uniQure Announces 2016 Financial Results and Provides Update on Company Progress
March 15, 2017 07:00 ET
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 15, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with...
uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
March 03, 2017 07:00 ET
|
uniQure N.V.
-- Lexington, MA-based Gene Therapy Facility Recognized for Enabling Manufacturing Excellence -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V....
uniQure Announces Presentations at Upcoming March Conferences
March 01, 2017 07:00 ET
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Presentations at Upcoming February Conferences
February 06, 2017 07:00 ET
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced presentations at the following...
uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B
January 30, 2017 07:00 ET
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 30, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that AMT-060, its proprietary,...
uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs
January 25, 2017 07:00 ET
|
uniQure N.V.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 25, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Alexander Kuta,...
uniQure Outlines Key Initiatives for 2017 and Vision for 2018
January 09, 2017 07:00 ET
|
uniQure N.V.
-- Preparations Underway for Late-Stage Development in Hemophilia B-- Three Clinical-Stage Programs by 2018 Including One Pivotal and Two Proof-of-Concept Studies-- Company Strengthened Following...
uniQure Appoints Matthew Kapusta as Chief Executive Officer
December 19, 2016 07:00 ET
|
uniQure N.V.
uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that its Board of Directors has unanimously approved the appointment of Matthew Kapusta as Chief Executive Officer...
uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
December 03, 2016 15:51 ET
|
uniQure N.V.
-- Second-dose Cohort Demonstrates Dose Response with All Patients Free of Prophylactic FIX Replacement Therapy and Only One Spontaneous Bleed Reported -- Low-Dose Cohort Shows Sustained...
uniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School
December 02, 2016 07:04 ET
|
uniQure N.V.
Amsterdam, The Netherlands, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Lexington, MA and Amsterdam, the Netherlands, December 2, 2016 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today...